Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12108450 | 1.00 | CYP1A2 (0.39) | CYP1A2TDP1CCR2KCNH2PARP1 | |
| SCHEMBL27271348 | 0.84 | CCR2 (0.38) | CYP1A2TDP1CCR2KCNH2PARP1 | |
| SCHEMBL10125636 | 0.82 | CCR2 (0.38) | CYP1A2TDP1CCR2KCNH2MMP1 | |
| SCHEMBL799809 | 0.82 | CCR2 (0.38) | CYP1A2TDP1CCR2KCNH2MMP1 | |
| SCHEMBL25728480 | 0.82 | CCR2 (0.38) | CYP1A2TDP1CCR2KCNH2MMP1 | |
| SCHEMBL14754513 | 0.80 | CCR2 (0.37) | CYP1A2TDP1CCR2KCNH2PARP1 | |
| SCHEMBL13448669 | 0.80 | CCR2 (0.37) | CYP1A2TDP1CCR2KCNH2PARP1 | |
| SCHEMBL16003094 | 0.80 | CCR2 (0.37) | CYP1A2TDP1CCR2KCNH2PARP1 | |
| SCHEMBL10037219 | 0.80 | — | — | |
| SCHEMBL48990 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | CYP1A2 4826/4885TDP1 842/4885CCR2 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.